Physician profile
Eric Suoja
NPI 1366403404
$3,363.96
in general payments reported to CMS, 2019-2025
30 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $731 · 2022: $849 · 2023: $589 · 2024: $624 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $372.26 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $314.77 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $237.41 | 2021-2024 | Nucala, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $188.29 | 2022-2024 | |
| Novo Nordisk INC | $164.31 | 2022-2025 | Wegovy |
| Amgen INC. | $133.02 | 2022-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $120.67 | 2024-2025 | |
| Pfizer INC. | $115.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.71 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.22 | 2021 | |
| Nestle Healthcare Nutrition INC. | $84.74 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.93 | 2022 | |
| Exact Sciences Corporation | $73.68 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $63.10 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $61.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.80 | 2023-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $42.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.41 | 2021 | |
| Medtronic, INC. | $34.41 | 2025 | Venaseal, Minimed 780g |
| Astellas Pharma US INC | $33.57 | 2022-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2021 | |
| Eisai INC. | $24.59 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $22.28 | 2025 | Amvuttra |
| Biohaven Pharmaceuticals, INC. | $21.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.15 | 2022 | |
| Dexcom, INC. | $20.90 | 2025 | Dexcom G6 Transmitter |
| Tms Neurohealth Centers INC. | $20.58 | 2025 | Tms Neurohealth Centers INC. |
| Aimmune Therapeutics, INC. | $20.30 | 2025 | Zenpep |
| Vertex Pharmaceuticals Incorporated | $19.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Suoja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.